Phase I, open label, single dose Safety and Pharmacokinetics study of SYM-1219 (Secnidazole) in Healthy Female Volunteers.

Trial Profile

Phase I, open label, single dose Safety and Pharmacokinetics study of SYM-1219 (Secnidazole) in Healthy Female Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Secnidazole (Primary)
  • Indications Bacterial vaginosis
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Symbiomix Therapeutics
  • Most Recent Events

    • 07 Nov 2016 According to a Symbiomix Therapeutics media release, data will be presented at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
    • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 04 Mar 2015 According to a Symbiomix Therapeutics media release, results will be presented at the annual meeting of the American Society of Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top